Head-to-head evidence
Beclomethasone (QVAR) vs Lodotra
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
Beclomethasone (QVAR)
Marketed by Teva Pharmaceutical Industries
NCT00109668 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with over 400 patients, which gives it solid design fundamentals. However, no results have been posted, and the record does not state what the primary outcome measure actually was, so the strength of the eventual evidence cannot yet be confirmed.
Lodotra · Rayos
Marketed by Amgen
NCT00686335 · Phase 2 · completed
This was a single-group, sequential (not randomized) study with no blinding and no true parallel control arm - patients simply switched from morning to evening dosing of the same drug class, and only 7 of 12 enrolled patients completed both periods for the efficacy analysis. The sponsor describes the study as exploratory with descriptive-only analysis and no statistical hypothesis testing, so despite numbers suggesting fewer nighttime awakenings with the evening formulation, this small, unblinded, uncontrolled design cannot serve as strong evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Beclomethasone (QVAR)'s landscape · Lodotra's landscape